Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 13;24(1):90–98. doi: 10.1093/neuonc/noab108

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Fig. 4 — Representative clinical course. The best response was judged as a CR. The treatment failure pattern was systemic metastasis. (A–C) The Gd-MRI taken just prior to BNCT, 4.5 months after BNCT, and 14 months after BNCT, respectively. (E, F) Gd and FLAIR-MRI taken 14 months after BNCT. (G, H) Gd-MRI and FLAIR-MRI taken 16 months after MRI, 2 cycles after bevacizumab treatment. (D) FDG-PET scan taken 21 months after BNCT, demonstrating pleural metastasis of meningioma. Abbreviations: BNCT = boron neutron capture therapy; CR = complete response; Gd-MRI = gadolinium-enhanced magnetic resonance imaging; FLAIR-MRI = fluid-attenuated inversion recovery-magnetic resonance imaging; FDG-PET = fluid-attenuated inversion recovery-magnetic resonance imaging.